Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 3, 2012, Pages 260-263

  Zhu, Cuiyun ^a   Zhang, Yongxin ^b   Shen, Yinzhong ^a   Siu, Gilman Kit Hang ^c   Wu, Wenjuan ^a   Qian, Xueqin ^a   Deng, Guilin ^a   Xu, Yan ^a   Lau, Ricky ^c   Fan, Xiaoyong ^a   Zhang, Wenhong ^b   Lu, Hongzhou ^a,b   Yam, Wing Cheong ^c  

^a SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fluoroquinolone resistance; Gyrase mutations; Mycobacterium tuberculosis

Indexed keywords

AMIKACIN; BACTERIAL DNA; CAPREOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM MUTANT; CHINA; DNA SEQUENCE; GENE STRUCTURE; GENE TARGETING; GEOGRAPHIC DISTRIBUTION; GYRA GENE; GYRB GENE; LUNG TUBERCULOSIS; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION RATE; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUINOLONE RESISTANCE DETERMINING REGION;

EID: 84862228470     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.03.025     Document Type: Article

References (23)

1. Chan R.C., Hui M., Chan E.W., Au T.K., Chin M.L., Yip C.K., et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007, 59:866-873.
2. Clinical and Laboratory Standards Institute (CLSI). Laboratory detection and identification of Mycobacteria; approved guideline. In Tentative standard M48-A. Wayne, PA: CLSI; 2008.
3. Cui Z., Wang J., Lu J., Huang X., Hu Z. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infectious Disease 2011, 11:78-82.
4. Escribano I., Rodriguez J.C., Llorca B., Garcia-Pachon E., Ruiz M., Royo G. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 2007, 53:397-401.
5. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
6. Hu W.Z., Li L.J., Guan L. Fluroquinolones in the treatment of lower respiratory tract infections. Chinese Joural of Antibiotics 1992, 17:122-125.
7. Huang T.S., Kunin C.M., Lee S.S.J., Chen Y.S., Tu H.Z., Liu Y.C. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005, 56:1058-1062.
8. Jiang S.C. Fluroquinolones in the treatment of bacterial digestive tract infections. Chinese Joural of Antibiotics 1992, 17:118-121.
9. Lau R.W., Ho P.L., Kao R.Y., Yew W.W., Lau T.C., Cheng V.C., et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother 2011, 55:608-614.
10. Louw G.E., Warren R.M., Gey van Pittus N.C., Leon R., Jimenez A., Hernandez-Pando R., et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011, 184:269-276.
11. Mokrousov I., Otten T., Manicheva O., Potapova Y., Vishnevsky B., Narvskaya O., et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008, 52:2937-2939.
12. Singh M., Jadaun G.P.S., Ramdas Srivastava K., Chauhan V., Mishra R., Gupta K., et al. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 2011, 133:535-540.
13. Sun Z., Zhang J., Zhang X., Wang S., Zhang Y., Li C. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2007, 31:115-121.
14. Takiff H.E., Salazar L., Guerrero C., Philipp W., Huang W.M., Kreiswirth B., et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994, 38:773-780.
15. Vien le T.M., Abuoun M., Morrison V., Thomson N., Campbell J.I., Woodward M.J., et al. Differential phenotypic and genotypic characteristics of qnrS1-harboring plaSTRids carried by hospital and community commensal enterobacteria. Antimicrob Agents Chemother 2011, 55:1798-1802.
16. Umubyeyi A.N., Rigouts L., Shamputa I.C., Fissette K., Elkrim Y., de Rijk P.W., et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007, 59:1031-1033.
17. Wise R. Maximizing efficacy and reducing the emergence of resistance. J Antimicrob Chemother 2003, 51(Suppl. 1):37-42.
18. World Health Organization (WHO). Guidelines for drug susceptibility testing for second line anti-tuberculosis drugs for DOTS plus: WHO/CDS/TB/2001.288. World Health Organization, Geneva, Switzerland; 2001.
19. World Health Organization (WHO). Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs: WHO/HTM/TB/2008.392. World Health Organization, Geneva, Switzerland; 2008.
20. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): global report on surveillance and response: WHO/HTM/TB/2010.3: World Health Organization, Geneva, Switzerland; 2010.
21. World Health Organization (WHO). Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report: WHO/HTM/TB/2011.3. World Health Organization, Geneva, Switzerland; 2011.
22. Xu P., Li X., Zhao M., Gui X., DeRiemer K., Gagneux S., et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 2009, 53:3170-3172.
23. Zhou T.L., Chen X.J., Zhou M.M., Zhao Y.J., Luo X.H., Bao Q.Y. Prevalence of plaSTRid-mediated quinolone resistance in Escherichia coli isolates in Wenzhou, Southern China, 2002-2008. Jpn J Infect Dis 2011, 64:55-57.